Recherche Clinique et Formation

Institut Cardiovasculaire Paris Sud

Atrial Fibrillation

Stroke

Aortic Valve Stenosis

Infarction

Coronary Artery Disease

Myocardial Ischemia

Myocardial Infarction

Heart Valve Diseases

Conformal Medical

Cordis

Rigshospitalet

Centre Hospitalier Universitaire de Besancon

University Hospital, Lille

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.

The CONFORM Pivotal Trial

Institut Cardiovasculaire Paris Sud | Recherche Clinique et Formation

Site insights

Work at this site?

Active trials

The CONFORM Pivotal Trial

Trial sponsors